Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Losartan Potassium

FDA-approved product (tablet, oral), marketed as Arbli, Cozaar, Losartan Potassium.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Losartan Potassium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Chronic kidney disease
  • Hypertension
  • Kidney disease
  • Proteinuria
  • Stroke

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Angiotensin ii receptor blockers (arbs), plain
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA47.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli33.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae11.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Losartan Potassium in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Losartan Potassium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes

    NCT07568574 · start 2026-03-12

    Registered record
    Registry ID
    NCT07568574
    Conditions
    Safety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes
    Interventions
    Testosterone Enanthate; Testosterone Cypionate; Testosterone Propionate; Sustanon (testosterone); Testosterone Gel; Methenolone Enanthate (Primobolan); Nandrolone Decanoate (Deca-Durabolin); Estradiol Patch; Estradiol Capsule; Progesterone Cream; Progesterone Capsule; Human Growth Hormone (hGH); EPO Darbepoetin (Aranesp); Meldonium; Modafinil; Mixed amphetamine salts (Adderall); Clomiphene; Anastrozole; Levothyroxine; Liothyronine; hCG; hMG; Atorvastatin; Rosuvastatin; Bisoprolol; Nebivolol; Metoprolol; Propranolol; Lisinopril; Enalapril; Furosemide; Chlorothiazide; Cabergoline; Metformin; Basal Insulin Glargine (long-acting); Telmisartan; Losartan
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Enrolling by invitation
    Start
    2026-03-12
    Completion
    2033-03-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSafety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes
    InterventionTestosterone Enanthate; Testosterone Cypionate; Testosterone Propionate; Sustanon (testosterone) +33 more
    PhaseNot applicable
    Registry statusEnrolling by invitation

  • Losartan to Improve Outcomes After Multi-ligament Knee Injury

    NCT06933706 · start 2025-10-01

    Registered record
    Registry ID
    NCT06933706
    Conditions
    Multi-ligament Knee Injury
    Interventions
    losartan 25 mg; Placebo capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-10-01
    Completion
    2029-09-30
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMulti-ligament Knee Injury
    Interventionlosartan 25 mg; Placebo capsule
    PhasePhase 2
    Registry statusRecruiting

  • Exploration of Postoperative Adjuvant Therapy for HCC Patients With Positive TB

    NCT07160361 · start 2025-10-01

    Registered record
    Registry ID
    NCT07160361
    Conditions
    Carcinoma, Hepatocellular
    Interventions
    Lenvatinib + losartan
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2025-10-01
    Completion
    2029-12-31
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Hepatocellular
    InterventionLenvatinib + losartan
    PhasePhase 4
    Registry statusNot yet recruiting

  • Heart Failure With Reduced Ejection Fraction Polypill Implementation Strategy in Sri Lanka

    NCT06831864 · start 2025-02-15

    Registered record
    Registry ID
    NCT06831864
    Conditions
    Heart Failure With Reduced Ejection Fraction
    Interventions
    HFrEF Polypill; Comparator Arm
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2025-02-15
    Completion
    2025-05-05
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure With Reduced Ejection Fraction
    InterventionHFrEF Polypill; Comparator Arm
    PhasePhase 1
    Registry statusCompleted

  • Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.

    NCT06364176 · start 2024-06-03

    Registered record
    Registry ID
    NCT06364176
    Conditions
    Cystic Fibrosis
    Interventions
    Losartan; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-06-03
    Completion
    2027-10
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis
    InterventionLosartan; Placebo
    PhasePhase 2
    Registry statusRecruiting

  • A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial)

    NCT06150560 · start 2024-04-01

    Registered record
    Registry ID
    NCT06150560
    Conditions
    Coarctation of Aorta; High Blood Pressure
    Interventions
    Losartan; Amlodipine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-04-01
    Completion
    2028-06-01
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoarctation of Aorta; High Blood Pressure
    InterventionLosartan; Amlodipine; Placebo
    PhasePhase 3
    Registry statusRecruiting

  • Ethosomal Gel Bearing Losartan 5% for Keloid Treatment

    NCT05893108 · start 2024-03-30

    Registered record
    Registry ID
    NCT05893108
    Conditions
    Keloid
    Interventions
    Ethosomal gel bearing losartan 5%; triamcinolone acetonide 10 mg/ml
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2024-03-30
    Completion
    2024-10-30
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKeloid
    InterventionEthosomal gel bearing losartan 5%; triamcinolone acetonide 10 mg/ml
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • Effect of Losartan on the Incidence and Severity of Chemotherapy-Induced Mucositis in Gastrointestinal Cancer Patients

    NCT05871333 · start 2023-07-17

    Registered record
    Registry ID
    NCT05871333
    Conditions
    Chemotherapy; Colorectal Cancer; Intestinal Mucositis; Oral Mucositis
    Interventions
    Losartan 50mg Tab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2023-07-17
    Completion
    2024-07-01
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChemotherapy; Colorectal Cancer; Intestinal Mucositis; Oral Mucositis
    InterventionLosartan 50mg Tab
    PhasePhase 2
    Registry statusUnknown

  • The Effect of Enalapril, Losartan or Not Antihypertensive on the Oxidative Status in Renal Transplant Recipients

    NCT05232370 · start 2022-01-01

    Registered record
    Registry ID
    NCT05232370
    Conditions
    Oxidative Stress
    Interventions
    Angiotensin converting enzyme inhibitor; Angiotensin Receptor Blockers
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2022-01-01
    Completion
    2022-01-06
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOxidative Stress
    InterventionAngiotensin converting enzyme inhibitor; Angiotensin Receptor Blockers
    PhasePhase 2
    Registry statusCompleted

  • NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

    NCT04539808 · start 2021-05-27

    Registered record
    Registry ID
    NCT04539808
    Conditions
    Pancreatic Adenocarcinoma; Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8; Stage I Pancreatic Cancer American Joint Committee on Cancer v8; Stage III Pancreatic Cancer American Joint Committee on Cancer v8; Stage IV Pancreatic Cancer American Joint Committee on Cancer v8
    Interventions
    Capecitabine; Fluorouracil; Irinotecan Hydrochloride; Leucovorin Calcium; Losartan Potassium; Oxaliplatin; Radiation Therapy; Resection; Diagnostic Imaging; Biospecimen Collection; Gemcitabine; Nab paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2021-05-27
    Completion
    2027-01-05
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Adenocarcinoma; Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8; Stage I Pancreatic Cancer American Joint Committee on Cancer v8; Stage III Pancreatic Cancer American Joint Committee on Cancer v8 +1 more
    InterventionCapecitabine; Fluorouracil; Irinotecan Hydrochloride; Leucovorin Calcium +8 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis

    NCT04815902 · start 2021-05-18

    Registered record
    Registry ID
    NCT04815902
    Conditions
    Osteoarthritis, Knee
    Interventions
    Fisetin; Losartan; Placebo - Losartan; Placebo Fisetin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2021-05-18
    Completion
    2025-06-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteoarthritis, Knee
    InterventionFisetin; Losartan; Placebo - Losartan; Placebo Fisetin
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • The COVID-RASi Trial (COVID-19)

    NCT04591210 · start 2021-01-27

    Registered record
    Registry ID
    NCT04591210
    Conditions
    COVID-19; Cardiovascular Diseases
    Interventions
    Angiotensin converting enzyme inhibitor; Angiotensin II Receptor Blockers
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-01-27
    Completion
    2024-12-30
    Enrolment
    372

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19; Cardiovascular Diseases
    InterventionAngiotensin converting enzyme inhibitor; Angiotensin II Receptor Blockers
    PhasePhase 3
    Registry statusCompleted

  • Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease

    NCT04394117 · start 2020-06-19

    Registered record
    Registry ID
    NCT04394117
    Conditions
    Coronavirus Disease 2019; COVID-19
    Interventions
    Angiotensin Receptor Blockers; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2020-06-19
    Completion
    2022-01-17
    Enrolment
    787

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronavirus Disease 2019; COVID-19
    InterventionAngiotensin Receptor Blockers; Placebo
    PhasePhase 4
    Registry statusCompleted

  • ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

    NCT04467931 · start 2020-01-19

    Registered record
    Registry ID
    NCT04467931
    Conditions
    Hypertension; COVID
    Interventions
    ACEI/ARB; Non-ACEI/ARB; ACEI; ARB
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-01-19
    Completion
    2020-12-31
    Enrolment
    22,213

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; COVID
    InterventionACEI/ARB; Non-ACEI/ARB; ACEI; ARB
    PhaseNot recorded
    Registry statusCompleted

  • The Role of Isolated Nocturnal Hypertension Pattern in Nondialysis CKD

    NCT03604003 · start 2018-11-30

    Registered record
    Registry ID
    NCT03604003
    Conditions
    Chronic Kidney Disease
    Interventions
    potassium losartan
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2018-11-30
    Completion
    2023-12-30
    Enrolment
    252

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Kidney Disease
    Interventionpotassium losartan
    PhaseNot applicable
    Registry statusUnknown